Nuvectis Pharma, Inc. NVCT 深 滬
已收盤 09-26 16:00:00 美东时间
6.08
+0.130
+2.18%
華盛通- 最 高6.1388
- 今 開6.02
- 成交量 6.18万股
- 最 低 5.96
- 昨 收 5.95
- 總市值 1.55亿
- 52周最高 11.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.44
- 委 比 -2.89%
- 總股本 2545.68万
- 歷史最高 20.92
- 量 比 0.37
- 振 幅 3.01%
- 歷史最低 3.08
- 每 手 1
- 風險率 1.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez, a seasoned biotech executive with over 30 years of experience in healthcare, finance, and industry, joins Nuvectis as it advances its Phase 1b program for NXP900, an innovative precision medicine targeting advanced and treatment-resistant cancers. Ron Bentsur, Nuvectis' CEO, highlighted Dr. Sanchez's expertise and his potent...
09-25 12:00
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Nuvectis Pharma, Inc. announced its participation in the upcoming H.C. Wainwright Global Investment Conference. Ron Bentsur, the company's CEO, will deliver a presentation on September 5, 2025, available for on-demand viewing. The company will also engage in virtual one-on-one meetings from September 8-10, 2025. Nuvectis specializes in developing precision medicines for unmet medical needs in oncology, with two clinical-stage drug candidates: NXP...
09-04 11:30
13F持仓新鲜出炉！巴菲特减持苹果，贝莱德、高盛买入硬核科技股
近日，各大机构向美国证券交易委员会(SEC)陆续提交13F报告，披露了二季度所持美股股票和持仓规模。 其中，股神巴菲特15.7亿重仓医疗巨头、继续减持苹果，高瓴...
08-15 09:16
Nuvectis Pharma (NVCT) Gets a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Ph...
08-12 22:15
Nuvectis Launches Phase 1b Trial Of NXP900 In Advanced Solid Tumors And Resistant NSCLC
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and
08-12 04:44
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
Nuvectis Pharma announced the initiation of the Phase 1b program for NXP900, focusing on evaluating its efficacy as a single agent in advanced solid tumors with specific genetic alterations and in combination with EGFR/ALK inhibitors for NSCLC patients resistant to these treatments. The program includes a single-agent component targeting YES1 amplified or FAT1 mutated NSCLC, NF2 mutated mesothelioma and renal cancer, and other solid tumors with r...
08-11 20:30
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma reported successful completion of NXP900's Phase 1a and drug-drug interaction studies, advancing to Phase 1b, with a strengthened cash position of $39 million after ATM share acquisition. The company plans to explore NXP800 in additional cancer types. Net loss for Q2 2025 was $6.3 million, with cash increasing to $26.8 million due to public offerings. Stock closed at $7.60, up 13.4% from $6.71.
08-05 11:30
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) stock rose 62.6% to $8.78 during Thurs...
07-31 20:08
Nuvectis Pharma Shared Final Clinical Data Update From The Phase 1b Study Of NXP800 In Recurrent, Platinum Resistant, ARID1a-mutated Ovarian Cancer And Reported On The Progress Towards The Initiation Of The Phase 1b Program For NXP900
As part of the NXP800 Phase 1b study, 17 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer were treated with NXP800 at the target dose of 75 mg/day, administered intermittently or daily, with
07-31 19:48
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
Nuvectis Pharma provided updates on NXP800 and NXP900. NXP800 showed partial responses and stable disease in ovarian cancer, with thrombocytopenia managed via intermittent dosing. The company is evaluating its potential in other cancers. NXP900 completed successful DDI and Phase 1a studies, with plans for Phase 1b initiation soon. The company prioritizes advancing NXP900 while exploring NXP800 opportunities elsewhere.
07-31 11:45
